Global private equity major TPG has finalized its exit from Sai Life Sciences, divesting its stake in the Hyderabad-based contract research and manufacturing services (CRAMS) firm for Rs. 2,675 crore. The deal marks a significant monetization for TPG, which had invested in Sai Life Sciences nearly a decade ago, and underscores the growing investor appetite for India’s pharmaceutical and life sciences sector.